Exopharm Valuation
Is EX1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EX1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate EX1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate EX1's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EX1?
Key metric: As EX1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is EX1's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | AU$3.39m |
| Market Cap | AU$4.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | -0.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does EX1's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.7x | ||
VBS Vectus Biosystems | 3.6x | n/a | AU$4.2m |
NC6 Nanollose | 9.6x | n/a | AU$2.9m |
NSB NeuroScientific Biopharmaceuticals | 2.3x | n/a | AU$5.4m |
PAB Patrys | 7.4x | n/a | AU$8.2m |
EX1 Exopharm | 1.4x | n/a | AU$4.8m |
Price-To-Sales vs Peers: EX1 is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (5.6x).
Price to Sales Ratio vs Industry
How does EX1's PS Ratio compare vs other companies in the AU Biotechs Industry?
Price-To-Sales vs Industry: EX1 is good value based on its Price-To-Sales Ratio (1.4x) compared to the Australian Biotechs industry average (10x).
Price to Sales Ratio vs Fair Ratio
What is EX1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate EX1's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
AVITA Medical
US$343.1m
Operates as a regenerative medicine company in the United States and internationally.
AVH
US$3.97
7D
5.0%
1Y
16.4%
Medical Developments International
AU$46.8m
Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.
MVP
AU$0.41
7D
-2.4%
1Y
-45.0%
Neuren Pharmaceuticals
AU$1.6b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$12.37
7D
-9.6%
1Y
-17.8%